Effects of striatal 5-HT1AR stimulation on
extracellular nigral GABA in a D1R-mediated model of dyskinesia. Rats
in Experiment 2 received unilateral 6-OHDA of the MFB and 3 weeks
later were primed with the D1R agonist SKF81297 (SKF; 0.8 mg/kg, sc)
every 2–3 days for a total of 3 days. Dyskinetic rats (N = 26) underwent a microdialysis procedure including 40
min baseline, 120 min vehicle treatment, 120 min drug treatment, and
60 min postdrug treatment sampling (dialysate collected every 20 min).
Intrastriatal drug infusion included: Vehicle (VEH; aCSF), the full
5-HT1AR agonist ±8-OH-DPAT (DPAT; 7.5 mM), or combined
DPAT (7.5 mM) + the 5-HT1AR antagonist WAY100635 (WAY;
4.6 mM), followed 10 min later by systemic treatment injections of
Vehicle (VEH; 20% DMSO, 0.9% NaCl) or SKF. ALO AIMs and rotations
were observed during this time. Treatment groups consist of n = 5–9/treatment group. (A) Lines depict the means
(expressed as % baseline ± SEM) of nigral GABA. (B) Bars depict
the means (expressed as % baseline ± SEM) of nigral GABA during
the 120 min of vehicle (VEH (aCSF) + VEH) and 120 min of drug treatments.
Effects over time were determined by two-way mixed design ANOVAs,
main effects for treatment collapsed across time were analyzed with
one-way ANOVAs, and LSD post hoc tests were utilized. *p < 0.05 vs VEH + SKF; +p < 0.05 vs DPAT (7.5
mM) + WAY (4.6 mM) + SKF. #p < 0.05 vs VEH + VEH;
×p < 0.05 vs DPAT (7.5 mM) + VEH.